Details of the Drug Reposition

General Information of This Drug (ID: DMRKTCP)

Drug Name
Retifanlimab   DMRKTCP
Synonyms MGA012; INCMGA0012
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Neuroendocrine cancer DISVGJET 2B72.1 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-small-cell lung cancer DIS5Y6R9 2C25.Y Phase 3 [2]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Metastatic colorectal cancer DIS18R3K 2B91 Phase 2 [3]
Merkel cell carcinoma DISDJJ4U 2C34 Phase 2 [4]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [5]
Penile squamous cancer DISR7YB5 2C81 Phase 1 [6]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761334.
2 ClinicalTrials.gov (NCT04203511) INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301). U.S. National Institutes of Health.
3 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
4 ClinicalTrials.gov (NCT03599713) A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201). U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT04231981) Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) (ORPHEUS). U.S. National Institutes of Health.